Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Metabolic and kinetic considerations in the use of (/sup 125/I)HIPDM for quantitative measurement of regional cerebral blood flow

Journal Article · · J. Cereb. Blood Flow Metab.; (United States)
The metabolic degradation and the kinetics of the cerebral uptake of N,N,N'-trimethyl-N'-(2-hydroxy-3-methyl-5-(/sup 125/I)iodobenzyl)-1, 3-propanediamine ((/sup 125/I)HIPDM) have been studied in conscious, adult male Sprague-Dawley rats to determine its suitability as a tracer for the quantitative measurement of regional CBF (rCBF). rCBF was calculated by the indicator fractionation and the tissue equilibration methods in experiments of different durations up to 1 h. The values of rCBF obtained with (/sup 125/I)HIPDM were compared with those obtained in concurrent measurements with (/sup 14/C)iodoantipyrine in the same animals. Results of the experiments demonstrate that (/sup 125/I)HIPDM is an inadequate tracer for use with the indicator fractionation method and that any method that employs (/sup 125/I)HIPDM for the determination of rCBF must take into account its metabolic degradation, diffusion limitations, and bidirectional flux across the blood-brain barrier. With the tissue equilibration method, consistent determinations of rCBF may be possible with (/sup 125/I)HIPDM by measurement of the time course of its concentration in arterial blood, corrected for the presence of /sup 125/I-labeled metabolic products, and its concentration in the brain at any time up to 1 h after its administration. The method may be adapted to measure rCBF in humans by means of single-photon emission tomography with (/sup 123/I)HIPDM.
Research Organization:
National Institute of Mental Health, Bethesda, MD
OSTI ID:
5612765
Journal Information:
J. Cereb. Blood Flow Metab.; (United States), Journal Name: J. Cereb. Blood Flow Metab.; (United States) Vol. 5:1; ISSN JCBMD
Country of Publication:
United States
Language:
English